By Ben Butkus

Quest Diagnostics said this week that its laboratory-developed XSense test for fragile X syndrome has been approved by New York State's Department of Health.

With the approval, Quest can offer the test to physicians in New York as well as in all other US states, as New York is the only state with an independent regulatory review process for lab-developed tests, which are also regulated at the federal level under the Clinical Laboratory Improvement Amendments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.